SubsidieMeestersELEM Virtual Heart Populations for Supercomputers
ELEMs V.Heart is a supercomputer platform for in-silico clinical trials using digital avatars to evaluate therapy outcomes, enhancing safety, efficacy, and precision medicine while reducing trial risks.
Projectdetails
Introduction
ELEMs V.Heart is a supercomputer-based platform to perform massive in-silico clinical trials on populations of digital avatars generated through a database of real medical data, to study the outcomes of different therapies.
Capabilities
It assesses the safety and efficacy of novel therapeutics, devices, or drugs by computing thousands of scenarios. Current capability covers:
- Classic or leadless pacing
- Cardiac pumps
- Cardiac safety of drugs
Future Plans
Our plan is to add new therapies whilst increasing the range of our patented virtual population technology.
Benefits
V.Heart generates unparalleled medical insights and new evidence for biomedical professionals whilst shortening time to market and reducing business and patient risks.
Impact on Testing
It narrows the scope for animal testing and tapers real human trials by evaluating clinical study endpoints much faster and earlier in the development process.
Conclusion
Eventually, digital avatars become a Digital Twin of any given patient used as a predictive tool for precision medicine.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.482.096 |
| Totale projectbegroting | € 3.545.852 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ELEM BIOTECH SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
VISUALIZACIÓN DE BIOPOTENCIALES PARA EQUIPOS CARDIOLÓGICOSVR-CARDIO is an innovative medical tool that uses AR/VR for precise visualization and diagnosis of arrhythmia, enhancing cardiac ablation speed and accuracy. | EIC Accelerator | € 2.499.999 | 2022 | Details |
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patientsreBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Confident®, the digital simulation platform that revolutionizes cardiovascular interventionsConfident is an AI-driven platform that creates 3D virtual models for cardiovascular interventions, enabling personalized treatment planning to improve patient outcomes and reduce surgical risks. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AIImplicity is developing an AI-driven platform to predict heart failure events using cardiac device data, enhancing patient care and reducing hospitalizations through tailored insights and management tools. | EIC Accelerator | € 2.488.359 | 2025 | Details |
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the marketThe Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation. | EIC Accelerator | € 2.500.000 | 2022 | Details |
VISUALIZACIÓN DE BIOPOTENCIALES PARA EQUIPOS CARDIOLÓGICOS
VR-CARDIO is an innovative medical tool that uses AR/VR for precise visualization and diagnosis of arrhythmia, enhancing cardiac ablation speed and accuracy.
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Confident®, the digital simulation platform that revolutionizes cardiovascular interventions
Confident is an AI-driven platform that creates 3D virtual models for cardiovascular interventions, enabling personalized treatment planning to improve patient outcomes and reduce surgical risks.
Development and clinical evaluation of an end-to-end Heart Failure management solution powered by predictive AI
Implicity is developing an AI-driven platform to predict heart failure events using cardiac device data, enhancing patient care and reducing hospitalizations through tailored insights and management tools.
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market
The Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Using CARDIac simulations to run in-silicO clinical TRIALSThis project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials. | ERC Starting... | € 1.499.423 | 2022 | Details |
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Haalbaarheidsonderzoek EnatomVIEMR vernieuwt het Enatom-platform voor anatomisch onderwijs door het toegankelijk te maken op diverse apparaten en besturingssystemen, met behoud van hoge detailniveaus. | Mkb-innovati... | € 20.000 | 2020 | Details |
Engineered multi-well platforms integrating biochemical and biophysical cues for the functional maturation and electrophysiological monitoring of cardiac tissue models.EMPATIC aims to develop a user-friendly multi-well platform for in vitro modeling of mature human cardiac tissues, enhancing cardiomyocyte maturation and enabling non-invasive electrophysiological monitoring. | ERC Proof of... | € 150.000 | 2024 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Using CARDIac simulations to run in-silicO clinical TRIALS
This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Haalbaarheidsonderzoek Enatom
VIEMR vernieuwt het Enatom-platform voor anatomisch onderwijs door het toegankelijk te maken op diverse apparaten en besturingssystemen, met behoud van hoge detailniveaus.
Engineered multi-well platforms integrating biochemical and biophysical cues for the functional maturation and electrophysiological monitoring of cardiac tissue models.
EMPATIC aims to develop a user-friendly multi-well platform for in vitro modeling of mature human cardiac tissues, enhancing cardiomyocyte maturation and enabling non-invasive electrophysiological monitoring.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.